The
World Leader in ECG Technology
|
|
|
The
World Leader in ECG Technology |
|
|
eResearchTechnology (eRT) and Mortara Instrument Announce Completion of a new Digital Electrocardiogram Process Mortara Instrument's new 12XML module and eRT’s EXPeRT Data Management System Facilitate Compliance with new Proposed FDA Standard for Assessing Cardiac Safety of New Drugs MILWAUKEE, WI, PHILADELPHIA, PA, USA 21 November 2001 Mortara Instrument and eResearchTechnology (eRT) (NASDAQ:ERES) announced today a digital ECG solution that facilitates compliance with the new proposed FDA standard for providing digital ECG data to define cardiac safety of new drugs. The digital ECG solution, is based on the interaction between eRT’s digital processing system, EXPeRT and Mortara's E-Scribe/NT ECG System, which incorporates a new module,12XML, designed specifically to support the collection of digital ECG data for clinical trials. With the 12XML module, the EXPeRT and E-Scribe/NT systems provide a complete solution available for digital ECG acquisition, transmission and export functionality according to the new proposed FDA standard. Justin L. Mortara, Ph.D., Vice President of Sales and Marketing for Mortara Instrument commented, "The collaboration between eResearchTechnology and Mortara is an example of two leaders in their respective fields demonstrating the ability to quickly identify and implement solutions. eRT identified what was needed from an ECG device manufacturer and Mortara responded by quickly implementing the necessary customization to meet those requirements." Mortara added, "Mortara Instrument has a strong history of providing customized ECG solutions to medical device companies worldwide on an OEM basis." Jeffrey Litwin, M.D. Sr. Vice President and Chief Medical Officer of eRT noted, "With the Mortara system ECG data can be digitally obtained at the clinical site where drugs are evaluated for safety and then transmitted to a centralized digital ECG laboratory like eRT. eRT will provide the analyzed data in the FDA format to sponsors who will provide this data as part of formal submissions to the FDA to obtain marketing approval for their new drugs. Utilizing Mortara's superior ECG technology and working with them to implement the proposed FDA standard will allow eRT to support Sponsors with all the ECG data services they will require. This capability, coupled with eRT’s new reporting tool, the ECG Digital Community, places us in an excellent position to deliver unique services to our clients." David W. Mortara, Ph.D., one of the world’s leading figures in ECG algorithm development, founded Mortara Instrument in 1982. Mortara Instrument's headquarters are located in Milwaukee, Wis., with European operations based in Bologna, Italy. Mortara Instrument is distinguished in the field of non-invasive cardiology for the innovations that are the core of the company's complete line of ECG products. These product innovations include the integration of 12-lead ECG technology in bedside monitoring, wireless stress testing, Holter and telemetry monitoring systems. For additional information on Mortara technology, please contact Mark Mentzer Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com), is a business-to-business provider of integrated software applications and technology consulting services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (EKG) services on a global basis. The Company also offers Internet and other technology-based solutions designed to streamline the clinical trial process by enabling its customers to automate and integrate many parts of the clinical trial. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Registration Statement on Form S-1 and in its Reports on Forms 10-K and 10-Q filed with the Securities Exchange Commission (SEC). Contact: Joan
Sterlacci 908-704-8010 X134 Matt Hayden 843-272-4653 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||
